390results about "Fused cells" patented technology

Recombinant NK cells, and especially recombinant NK-92 cells express a chimeric antigen receptor (CAR) having an intracellular domain of FcεRIγ. Notably, CAR constructs with an intracellular domain of FcεRIγ had a substantially prolonged duration of expression and significantly extended cytotoxicity over time. The CAR may be expressed from RNA and DNA, preferably as a tricistronic construct that further encodes CD16 and a cytokine to confer autocrine growth support. Advantageously, such constructs also enable high levels of transfection and expression of the recombinant proteins and provide a convenient selection marker to facilitate rapid production of recombinant NK / NK-92 cells.

Provided is the use of a protein derived from wheat and a biomaterial related thereto in increasing the yield per plant and grain protein content of a crop. The protein is designated as SWEET11, and may be a protein having an amino acid sequence as shown in sequence 9, sequence 6 or sequence 3 in the sequence listing. The wheat SWEET11 protein (TaSWEET11) is over-expressed in the Zhengmai 7698 wheat variety (nationally approved), and it is found that the over-expression of TaSWEET11 can significantly improve the thousand-grain weight of wheat grains and increase the yield. In addition, the over-expression of TaSWEET11 also increases the protein content in the wheat grain, significantly improving the grain quality while increasing the yield. The TaSWEET11 protein can be used for breeding and quality improvement of crops.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.

The present disclosure is directed to human IgE antibodies and fragments thereof binding to galactose-α-1,3-galactose, a known red meat allergen, and methods for use thereof.

Provided herein are antibodies and antibody fragments that bind to human TNFRSF25. The antibodies may be monoclonal and / or biparatopic antibodies and / or single- chain fragment variable (scFv) antibodies. Methods of treating or preventing diseases or disorders associated with inflammation and / or autoimmunity are provided, comprising administering to a patient in need thereof an effective amount of a human TNFRSF25- binding antibody.

This invention provides antibodies or functional antibody fragments or probes thereof targeting a unique set of antigens recognized in cancer. The invention comprises a nucleotide sequence derived from the L2A5 monoclonal antibody. The antibodies or functional antibody fragments or probes thereof include variable heavy chain domains and variable light chain domains having the amino acid sequences provided herein. The DNA / amino acid sequence binding is unique and has never been previously described. The invention further provides antibodies or functional antibody fragments or conjugates or recombinant proteins useful for the detection, treatment, and prevention of human diseases, including cancer.

The present invention relates to a novel anti-CD40 antibody and use thereof and, more specifically, to a novel anti-CD40 antibody and use thereof, wherein the antibody comprises a complementarity determining region of a specific sequence and exhibits an excellent antagonistic effect by blocking CD40-CD40L signaling. The novel anti-CD40 antibody of the present invention exhibits an excellent antagonistic effect by blocking CD40-CD40L signaling, and thus can be widely used as a preparation for preventing or treating various diseases, such as autoimmune diseases and chronic inflammatory diseases, and as a preparation for inhibiting immune rejection at the time of transplantation.

The invention belongs to the technical field of biology, and particularly relates to a hybridoma cell strain capable of secreting a clostridium perfringens ETX monoclonal antibody with neutralizing activity and application of the hybridoma cell strain. On the basis of natural toxin, an indirect ELISA (enzyme-linked immunosorbent assay) detection method is established by utilizing a non-toxic ETX single amino acid site protein mutant, and a series of hybridoma cell strains secreting an anti-clostridium perfringens ETX monoclonal antibody are screened; the hybridoma cell strain can stably and efficiently secrete a monoclonal antibody with neutralizing activity and a monoclonal antibody without neutralizing resistance respectively, and large-scale batch production can be realized. According to the present invention, the clostridium perfringens ETX monoclonal antibody is firstly utilized to establish the ETX antigen ELISA detection method, and the method has characteristics of simple sample operation, low cost, rapid reaction, strong specificity and the like, can provide the reference for the diagnosis of clostridium perfringens, and provides the basis for the research of the related vaccine potency test substitution method.

The invention discloses a monoclonal antibody which is specifically combined with a microtubule associated protein tau (microtubule associated protein with 217 Thrphorylation, pTau217) of which the 217 site is phosphorylated by threonine, and a preparation method of the monoclonal antibody. The invention provides an amino acid sequence of a variable domain of the monoclonal antibody, and an amino acid sequence of a complementary determining region (CDR) contained in the amino acid sequence of the variable domain of the monoclonal antibody. The monoclonal antibody disclosed by the invention has the capability of specifically recognizing and remarkably combining pTau217, and can be used for developing and producing pTau217 clinical in vitro diagnosis (IVD) medical equipment products based on an immunological detection principle as a reagent raw material.

The present invention provides an IL13RA2-targeting herpes simplex virus in which an anti-IL13RA2 antibody or an antigen-binding fragment thereof is presented on the viral surface. Also provided is an anti-IL13RA2 antibody or an antigen-binding fragment thereof capable of specifically recognizing tumor cells.

Provided herein are antibodies and antigen binding portions thereof that specifically bind the 4Ig isoform of B7 homolog 3 protein (B7-H3), various compositions of such antibodies or antigen binding portions thereof, and recombinant nucleic acids encoding the antibodies and antigen binding portions thereof. Also provided are methods of using the antibodies or antigen binding portions thereof in therapeutics and diagnostics for cancer or inflammation.

Antibodies and antigen binding fragments thereof that specifically recognize and bind an epitope of elastin that is exposed and accessible in degraded elastic fiber are described. The antibodies and / or antigen binding fragments can be operably linked to a secondary component, including biologically active agents such as therapeutics and / or imaging agents. Optionally, the antibodies and / or antigen binding fragments thereof can be attached to a surface of a carrier, such as a particle, for specific binding and delivery of the carried agents to degraded elastic fiber.

The present invention relates to bispecific antibodies against claudin 18.2 and CD3, pharmaceutical compositions comprising said bispecific antibodies, and related uses in the treatment of cancer.

The present invention provides a novel anti-Aβ antibody capable of detecting an Aβ related peptide, a method for measuring an Aβ related peptide in a biological sample by immunochemically using the above-mentioned novel anti-Aβ antibody, and a kit. A monoclonal antibody that recognizes an Aβ related peptide, and is produced by a hybridoma deposited under the accession number NITE BP-02998 at the NITE Patent Microorganisms Depositary of the National Institute of Technology and Evaluation. An antibody-immobilized carrier that includes a carrier and the monoclonal antibody defined in claim 1 bound to the carrier. A kit for measuring an Aβ related peptide, comprising the antibody-immobilized carrier.

Disclosed herein are reagents, reagent kits, and culture media for activating and expanding immune cells in vitro. In some embodiments, the reagents, reagent kits, and culture media comprise a Quillaja saponin. In other embodiments, the reagents, reagent kits, and culture media comprise a squalene-based emulsion. Also disclosed are methods for activating and expanding immune cells in vitro using the reagents, reagent kits, and culture media.

This invention discloses a hybridoma cell line that secretes anti-polystyrene monoclonal antibodies and its applications. The hybridoma cell line includes PS-8, classified as Hybridoma cell line PS-8. The accession number for PS-8 is CCTCC NO: C2024144, the accession date is May 10, 2024, and the depositary institution is the China Center for Type Culture Collection (CCTCC), located at Wuhan University, No. 299 Bayi Road, Wuchang District, Wuhan City, Hubei Province. The hybridoma cell line provided by this invention can stably secrete anti-polystyrene monoclonal antibodies with high titer, good specificity, and high sensitivity, making it suitable for detection in reagent kits and possessing potential application value.

To provide recombinant DNA molecules and constructs, as well as their nucleotide sequences, useful for modulating gene expression in plants.SOLUTION: The present invention provides novel synthetic gene regulatory elements for use in plants. The invention also provides recombinant DNA molecule constructs comprising the regulatory elements. The invention further provides transgenic plant cells, plants, and seeds comprising the regulatory elements. In one embodiment, the regulatory elements are operably linked to a transcribable DNA molecule. In certain embodiments, the transcribable DNA molecule may be heterologous with respect to the regulatory sequence. The invention also provides methods of using the regulatory elements, and making and using recombinant DNA molecules comprising the regulatory elements, as well as transgenic plant cells, plants, and seeds comprising the regulatory elements operably linked to a transcribable DNA molecule.SELECTED DRAWING: None

Provided herein are cells, enzymes, and methods for improved cannabinoid production.

Aspects of the disclosure provide for devices and methods of use thereof for detecting the presence of 14-3-3η protein in capillary blood samples from subjects suspected of having or at risk of developing arthritic conditions. In an example, a method includes obtaining a capillary blood sample from such a subject, and applying the capillary blood sample to a lateral flow device under conditions sufficient for formation of an immunocomplex comprising an immobilized anti-14-3-3η antibody coupled to a 14-3-3η protein that is further coupled to a labeled anti-14-3-3η antibody, wherein formation of the immunocomplex, and visualization thereof, is indicative of the arthritic condition.

To provide an antibody that inhibits the 5'→3' exonuclease activity of a DNA polymerase, or a fragment of the antibody.SOLUTION: Disclosed is an antibody that binds specifically to a 5'→3' exonuclease activity domain of a DNA polymerase, or a fragment of the antibody.SELECTED DRAWING: None

A cell culture device according to the present disclosure comprises: a culture chamber for culturing suspension cells; a flow path having a culture medium supply port and a culture medium discharge port, and provided adjacent to part or all of the outer side of at least one surface of the culture chamber; an oxygen permeable membrane provided to at least part of the flow path and / or the culture chamber; and a cell seeding port provided to at least part of the culture chamber.

The present invention discloses a genetically modified rodent whose immunoglobulin light chain locus is modified so as to comprise a single rearranged human immunoglobulin light chain gene V / J gene upstream of a mouse Kappa light chain locus constant region, a mouse variable region sequence cannot bind to an endogenous constant region to form a complete mouse light chain antibody, the rodents are capable of normally reproducing and producing human light chain-containing antibodies. The invention also provides a method of making the genetically modified rodent and a use of the rodent.

Provided is a method for inducing the differentiation of pluripotent stem cells which are obtained by suspension culture with high quality and / or high efficiency.　The present invention pertains to a method for producing differentiated cells, the method comprising: a step in which thermal stimulation is applied to pluripotent stem cells after suspension culture of the pluripotent stem cells; a step in which the pluripotent stem cells are subsequently seeded in a culture medium that is different from a culture medium used in the suspension culture; and a step in which agregate mass formation and differentiation induction of the seeded pluripotent stem cells are performed.

Described are nucleic acids that can be used for guide nucleic acid expression such as nucleic acids that comprise a polII promoter; an expression gene that is operably associated with the polII promoter; and a guide nucleic acid that is in the 3' untranslated region (UTR) of the expression gene. The expression gene may have a length of about 200, 225, 250, 275, 300, 325, or 350 nucleotides to about 375, 400, 425, 450, 475, 500, 525, 550, 575, or 600 nucleotides.

The application discloses an anti-Oncorhynchus keta CD8 alpha monoclonal antibody and a preparation method thereof, the monoclonal antibody is secreted by a hybridoma cell strain CD8 alpha-5E3, a preservation unit is the China Center for Type Culture Collection, a preservation number is CCTCC NO: C2024283, and a preservation date is August 26, 2024. + The antibody is high in specificity and can be used for identifying, separating and researching the CD8 + T cells of the Oncorhynchus keta, which is helpful to reveal the immunological mechanism related to the function and cytotoxic effect of the CD8 + T cells of the Oncorhynchus keta, which is helpful to reveal the immunological mechanism related to the function and cytotoxic effect of the CD8 + T cells of the Oncorhynchus keta, which is helpful to reveal the immunological mechanism related to the function and cytotoxic effect of the CD8 + T cells of the Oncorhynchus keta, which is helpful to reveal the immunological mechanism related to the function and cytotoxic effect of the CD8 + T cells of the Oncorhynchus keta, which is helpful to reveal the immunological mechanism related to the function and cytotoxic effect of the CD8 + T cells of the Oncorhynchus keta, which is helpful to

The present application provides a method for identifying the immune state of a subject, and a use of a reagent for detecting an IL-1R2 level in a sample from a subject in the preparation of products for identifying the immune state of the subject. The present application further provides an antibody that binds to human IL-1R2 and a use thereof, and a hybridoma cell producing the antibody that binds to human IL-1R2 and a use thereof.

The present invention provides isolated polypeptides capable of specifically binding to a protein target selected from LGALS9, CRP, BTLA, SAA, EGF, or FGA, or to a peptide thereof, especially under urinary conditions, which may be used for predicting in a urine sample of a subject suspected of having an infection whether the infection is a bacterial infection or a viral infection. The present invention further provides methods of diagnostics and treatment using the isolated polypeptides, and suitable diagnostic kits.

The present invention relates to a monoclonal antibody or an antibody fragment thereof that binds to an extracellular region of FCRL1, a hybridoma that produces the antibody, a nucleic acid comprising a nucleotide sequence that encodes the antibody or the antibody fragment thereof, a cell transformed with a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment thereof using the hybridoma or the transformed cell, an antibody-drug conjugate comprising the antibody or the antibody fragment thereof, a therapeutic agent and a diagnostic agent, each of which comprises the antibody or the antibody fragment thereof, and a therapeutic method and a diagnostic method for a disease associated with FCRL1 using the antibody, the antibody fragment thereof, or the antibody-drug conjugate comprising the antibody or the antibody fragment thereof.

Provided herein are antibodies or antigen-binding portions thereof that bind to STEAP1 and uses thereof. The antibody provided by the invention can be combined with STEAP1 of human, cynomolgus monkeys or mice, and the antibody provided by the invention has good affinity and internalization effect, and has the potential of preparing anti-tumor ADC drugs.

The present disclosure pertains to immune cells comprising chimeric antigen receptors (CARs) and methods of using immune cells comprising CARs.